Eric Abston Stephanie Hon Romy Lawrence Jeffrey Berman Praveen Govender Harrison W Farber
10.36141/svdld.v37i2.9343
Sarcoidosis Vasc Diffuse Lung Dis
2020;37(2):234-238.
ambition protocol sarcoid associated pulmonary hypertension ambrisentan pulmonary hypertension sarcoidosis tadalafil
CC BY-NC-SA
https://pubmed.ncbi.nlm.nih.gov/33093789/
Antihypertensive Agents / therapeutic use Arterial Pressure / drug effects Endothelin A Receptor Antagonists / therapeutic use Hypertension, Pulmonary / drug therapy Phenylpropionates / therapeutic use Phosphodiesterase 5 Inhibitors / therapeutic use Pulmonary Artery / drug effects Pyridazines / therapeutic use Sarcoidosis, Pulmonary / complications Tadalafil / therapeutic use
Antihypertensive Agents / therapeutic use Arterial Pressure / drug effects Endothelin A Receptor Antagonists / therapeutic use Hypertension, Pulmonary / drug therapy Phenylpropionates / therapeutic use Phosphodiesterase 5 Inhibitors / therapeutic use Pulmonary Artery / drug effects Pyridazines / therapeutic use Sarcoidosis, Pulmonary / complications Tadalafil / therapeutic use Case Reports Adult Aged Drug Therapy, Combination Female Humans Hypertension, Pulmonary / diagnosis Hypertension, Pulmonary / etiology Hypertension, Pulmonary / physiopathology Lung Transplantation Male Middle Aged Pulmonary Artery / physiopathology Retrospective Studies Sarcoidosis, Pulmonary / diagnosis Treatment Outcome Antihypertensive Agents Endothelin A Receptor Antagonists Phenylpropionates Phosphodiesterase 5 Inhibitors Pyridazines Tadalafil ambrisentan
PMC7569547
33093789
Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
2020